Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV002272048 | SCV000484423 | pathogenic | Muscular dystrophy-dystroglycanopathy | 2022-02-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with POMGNT1-related disorders. (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2: 5 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar, DECIPHER). (SP) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. It has been reported as pathogenic and likely pathogenic in ClinVar in individuals with POMGNT1-related disorders. (SP) 1209 - This variant has been shown to be both maternally and paternally inherited (biallelic) (by segregation analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Gene |
RCV000578838 | SCV000680688 | pathogenic | not provided | 2024-03-06 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 19299310, 26938784, 22554691, 31964843, 29453417, 28832562) |
Labcorp Genetics |
RCV001062800 | SCV001227623 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2023-11-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg215*) in the POMGNT1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POMGNT1 are known to be pathogenic (PMID: 19299310, 20816175, 21447391, 26908613, 27391550). This variant is present in population databases (rs386834034, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with muscular dystrophy-dystroglycanopathy (PMID: 22554691, 26938784, 28832562). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56604). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000578838 | SCV002544277 | pathogenic | not provided | 2022-06-01 | criteria provided, single submitter | clinical testing | POMGNT1: PVS1, PM3:Strong, PM2 |
Broad Center for Mendelian Genomics, |
RCV002272048 | SCV003761187 | pathogenic | Muscular dystrophy-dystroglycanopathy | 2023-01-24 | criteria provided, single submitter | curation | The p.Arg215Ter variant in POMGNT1 has been reported in at least two individuals with muscular dystrophy-dystroglycanopathy (PMID: 22554691, 26938784), and has been identified in 0.006% (2/34582) of Latino/Admixed American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs386834034). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID#: 56604) and has been interpreted as pathogenic/likely pathogenic by multiple labs. Of the two affected individuals reported, one was a compound heterozygote who carried a reported pathogenic variant in trans, which increases the likelihood that the p.Arg215Ter variant is pathogenic (PMID: 22554691, ClinVarID: 56610). cDNA sequencing analysis performed on affected tissue shows exon 7 skipping, which is out-of-frame exon (PMID:22554691). This nonsense variant leads to a premature termination codon at position 215, which is predicted to lead to a truncated or absent protein. Loss of function of the POMGNT1 gene is an established disease mechanism in autosomal recessive POMGNT1-associated muscular dystrophy-dystroglycanopathy. In summary, this variant meets criteria to be classified as pathogenic for POMGNT1-associated muscular dystrophy-dystroglycanopathy. ACMG/AMP Criteria applied: PVS1, PM2_supporting, PM3, PS3 (Richards 2015). |
Baylor Genetics | RCV003460643 | SCV004205949 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 | 2024-03-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005016347 | SCV005648514 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3; Retinitis pigmentosa 76 | 2024-04-23 | criteria provided, single submitter | clinical testing | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000050017 | SCV000082426 | probable-pathogenic | Muscle eye brain disease | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Counsyl | RCV000050017 | SCV001132463 | likely pathogenic | Muscle eye brain disease | 2014-01-02 | no assertion criteria provided | clinical testing | |
Counsyl | RCV000408610 | SCV001132464 | likely pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2014-01-02 | no assertion criteria provided | clinical testing | |
Counsyl | RCV000984294 | SCV001132465 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2O | 2014-01-02 | no assertion criteria provided | clinical testing | |
Counsyl | RCV000984295 | SCV001132466 | likely pathogenic | Retinitis pigmentosa 76 | 2014-01-02 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000050017 | SCV002089625 | pathogenic | Muscle eye brain disease | 2020-10-01 | no assertion criteria provided | clinical testing |